Overview

Phase I (PH I) Mad Refractory Solid Tumor Study

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, effect of food, and continue exploratory research of BMS-354825 in patients with solid tumors not responding to standard treatment, or for which no effective standard treatment exists.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Dasatinib